Enabling high performance
isolation of CTCs
Backed by
The Cytocatch™ technology has outstanding recovery rates, it has yields above 97% when processing blood samples spiked with tumor cells from prostate, breast, lung, and colorectal cancer cell lines.
​Label-free isolation of CTCs
Stop losing valuable information and forget about the limitations of capturing CTC subpopulations with diminished expression of epithelial markers.
​
The capture approach employed by the CytoCatch™ Isolation Platform is based on the differences in size and deformability between blood cells and CTCs. This allows the capture of CTCs whose epithelial phenotype is downregulated, in comparison to technologies that rely on specific antigen-antibody interactions, which typically use EpCAM (epithelial cell adhesion molecule) antibodies to selectively isolate CTCs.
​Label-free isolation of CTCs
Stop losing valuable information and forget about the limitations of capturing CTC subpopulations with diminished expression of epithelial markers.
​
The capture approach employed by the CytoCatch™ Isolation Platform is based on the differences in size and deformability between blood cells and CTCs. This allows the capture of CTCs whose epithelial phenotype is downregulated, in comparison to technologies that rely on specific antigen-antibody interactions, which typically use EpCAM (epithelial cell adhesion molecule) antibodies to selectively isolate CTCs.
Fully automated
The CytoCatch™ Isolation Platform automatically performs the necessary steps to process the sample and subsequently stain the collected cells with fluorescently labeled antibodies, increasing the reliability and reproducibility of the assay by preventing human errors and cell loss due to manual steps.
Fully automated
The CytoCatch™ Isolation Platform automatically performs the necessary steps to process the sample and subsequently stain the collected cells with fluorescently labeled antibodies, increasing the reliability and reproducibility of the assay by preventing human errors and cell loss due to manual steps.
Customize your experiments
Its powerful software enables the construction of custom processing protocols in a quick and easy manner without previous programming knowledge. Customize all the steps executed by the CytoCatch™ Isolation Platform during and after the processing of the sample.
Always reproducible
The CytoCatch™ Isolation Platform integrates multiple sensors and control algorithms to guarantee the correct processing of the sample, and hence ensure that the results are always reproducible.
FEATURES
Capable of handling large sample volumes
The CytoCatch™ Isolation Platform is capable of processing large sample volumes, up to 15 mL, which is optimal due to the extremely low concentration of CTCs in blood.
No sample pre-enrichment required
​Unlike other technologies, there is no need to perform any tedious pre-enrichment steps before the processing of the sample, avoiding the inherent cell loss related to these procedures.
Exceptionally fast
The time required to process a 15 mL blood sample is approximately 20 minutes.
DOWNSTREAM APPLICATIONS
The captured CTCs are compatible with a broad range of analysis techniques enabling DNA, RNA, and protein-based molecular profiling.
![scc280_scc-61_bf-day 1[223438-ALL].jpg](https://static.wixstatic.com/media/082c58_50590b31f4204a499fa9de8984924c1b~mv2.jpg/v1/crop/x_113,y_0,w_375,h_450/fill/w_269,h_323,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/scc280_scc-61_bf-day%201%5B223438-ALL%5D.jpg)
DOWNSTREAM APPLICATIONS
The captured CTCs are compatible with a broad range of analysis techniques enabling DNA, RNA, and protein-based molecular profiling.
Traditional & next generation sequencing
SPECIFICATIONS
